BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

301 related articles for article (PubMed ID: 30485478)

  • 21. Prognostic implications of neuroendocrine differentiation and hormone production in patients with Stage I nonsmall cell lung carcinoma.
    Pelosi G; Pasini F; Sonzogni A; Maffini F; Maisonneuve P; Iannucci A; Terzi A; De Manzoni G; Bresaola E; Viale G
    Cancer; 2003 May; 97(10):2487-97. PubMed ID: 12733148
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Pulmonary large cell neuroendocrine carcinoma with adenocarcinoma-like features: napsin A expression and genomic alterations.
    Rekhtman N; Pietanza CM; Sabari J; Montecalvo J; Wang H; Habeeb O; Kadota K; Adusumilli P; Rudin CM; Ladanyi M; Travis WD; Joubert P
    Mod Pathol; 2018 Jan; 31(1):111-121. PubMed ID: 28884744
    [TBL] [Abstract][Full Text] [Related]  

  • 23. The diagnostic utility of zinc E-box 1 (ZEB1) transcription factor for identification of pulmonary sarcomatoid carcinoma in cytologic and surgical specimens.
    Viswanathan K; Siddiqui MT; Borczuk AC
    J Am Soc Cytopathol; 2020; 9(1):55-61. PubMed ID: 31677963
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Insulinoma-associated protein 1 is a sensitive and specific marker of neuroendocrine lung neoplasms in cytology specimens.
    Doxtader EE; Mukhopadhyay S
    Cancer Cytopathol; 2018 Apr; 126(4):243-252. PubMed ID: 29360191
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Mucosal large cell neuroendocrine carcinoma of the head and neck regions in Japanese patients: a distinct clinicopathological entity.
    Kusafuka K; Abe M; Iida Y; Onitsuka T; Fuke T; Asano R; Kamijo T; Nakajima T
    J Clin Pathol; 2012 Aug; 65(8):704-9. PubMed ID: 22718848
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Ki-67 Index of 55% Distinguishes Two Groups of Bronchopulmonary Pure and Composite Large Cell Neuroendocrine Carcinomas with Distinct Prognosis.
    Milione M; Maisonneuve P; Grillo F; Mangogna A; Centonze G; Prinzi N; Pusceddu S; Garzone G; Cattaneo L; Busico A; Bossi P; Spaggiari P; Pellegrinelli A; Del Gobbo A; Ferrero S; Kankava K; Pruneri G; Rolli L; Roca E; Bercich L; Tironi A; Benvenuti MR; Gallazzi MS; Romano R; Berruti A; Pastorino U; Capella C
    Neuroendocrinology; 2021; 111(5):475-489. PubMed ID: 32365350
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Small cell carcinoma of the lung and large cell neuroendocrine carcinoma interobserver variability.
    den Bakker MA; Willemsen S; Grünberg K; Noorduijn LA; van Oosterhout MF; van Suylen RJ; Timens W; Vrugt B; Wiersma-van Tilburg A; Thunnissen FB
    Histopathology; 2010 Feb; 56(3):356-63. PubMed ID: 20459535
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Predictors of survival after operation among patients with large cell neuroendocrine carcinoma of the lung.
    Eichhorn F; Dienemann H; Muley T; Warth A; Hoffmann H
    Ann Thorac Surg; 2015 Mar; 99(3):983-9. PubMed ID: 25596870
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Spectrum of neuroendocrine carcinomas of the uterine cervix, including histopathologic features, terminology, immunohistochemical profile, and clinical outcomes in a series of 50 cases from a single institution in India.
    Rekhi B; Patil B; Deodhar KK; Maheshwari A; A Kerkar R; Gupta S; Tongaonkar HB; Shrivastava SK
    Ann Diagn Pathol; 2013 Feb; 17(1):1-9. PubMed ID: 22534245
    [TBL] [Abstract][Full Text] [Related]  

  • 30. An immunohistochemical study of cervical neuroendocrine carcinomas: Neoplasms that are commonly TTF1 positive and which may express CK20 and P63.
    McCluggage WG; Kennedy K; Busam KJ
    Am J Surg Pathol; 2010 Apr; 34(4):525-32. PubMed ID: 20182342
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Large-cell neuroendocrine carcinoma of the skin: ultrastructural and immunohistochemical findings.
    Nagase K; Kimura H; Yonekura N; Koba S; Inoue T; Narisawa Y
    J Cutan Pathol; 2016 Nov; 43(11):1067-1073. PubMed ID: 27514507
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Classifying Pulmonary and Urinary High-grade Neuroendocrine Carcinoma by CK7 Immunohistochemistry.
    Fan J; Li H; Zhou C; Xiong W; Villamil C; Ionescu D; Oo HZ; Contreras-Sanz A; Black PC; Wang G
    Appl Immunohistochem Mol Morphol; 2022 Jul; 30(6):459-468. PubMed ID: 35603802
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Stathmin-1 Is a Useful Diagnostic Marker for High-Grade Lung Neuroendocrine Tumors.
    Shimizu K; Goto Y; Kawabata-Iwakawa R; Ohtaki Y; Nakazawa S; Yokobori T; Obayashi K; Kawatani N; Yajima T; Kaira K; Mogi A; Hirato J; Nishiyama M; Shirabe K
    Ann Thorac Surg; 2019 Jul; 108(1):235-243. PubMed ID: 30910656
    [TBL] [Abstract][Full Text] [Related]  

  • 34. DLL3 expression in large cell neuroendocrine carcinoma (LCNEC) and association with molecular subtypes and neuroendocrine profile.
    Hermans BCM; Derks JL; Thunnissen E; van Suylen RJ; den Bakker MA; Groen HJM; Smit EF; Damhuis RA; van den Broek EC; ; Ruland A; Speel EJM; Dingemans AMC
    Lung Cancer; 2019 Dec; 138():102-108. PubMed ID: 31678831
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Comparison of four DLL3 antibodies performance in high grade neuroendocrine lung tumor samples and cell cultures.
    Brcic L; Kuchler C; Eidenhammer S; Pabst D; Quehenberger F; Gazdar AF; Popper H
    Diagn Pathol; 2019 May; 14(1):47. PubMed ID: 31109352
    [TBL] [Abstract][Full Text] [Related]  

  • 36. BAI3, CDX2 and VIL1: a panel of three antibodies to distinguish small cell from large cell neuroendocrine lung carcinomas.
    Bari MF; Brown H; Nicholson AG; Kerr KM; Gosney JR; Wallace WA; Soomro I; Muller S; Peat D; Moore JD; Ward LA; Freidin MB; Lim E; Vatish M; Snead DR
    Histopathology; 2014 Mar; 64(4):547-56. PubMed ID: 24266897
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Large Cell Neuroendocrine Carcinoma of the Prostate: A Systematic Review and Pooled Analysis.
    Tu X; Chang T; Nie L; Qiu S; Xu H; Huang Y; Bao Y; Liu Z; Yang L; Wei Q
    Urol Int; 2019; 103(4):383-390. PubMed ID: 30965328
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Two prognostically significant subtypes of high-grade lung neuroendocrine tumours independent of small-cell and large-cell neuroendocrine carcinomas identified by gene expression profiles.
    Jones MH; Virtanen C; Honjoh D; Miyoshi T; Satoh Y; Okumura S; Nakagawa K; Nomura H; Ishikawa Y
    Lancet; 2004 Mar; 363(9411):775-81. PubMed ID: 15016488
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Molecular Subtypes of Pulmonary Large-cell Neuroendocrine Carcinoma Predict Chemotherapy Treatment Outcome.
    Derks JL; Leblay N; Thunnissen E; van Suylen RJ; den Bakker M; Groen HJM; Smit EF; Damhuis R; van den Broek EC; Charbrier A; Foll M; McKay JD; Fernandez-Cuesta L; Speel EM; Dingemans AC;
    Clin Cancer Res; 2018 Jan; 24(1):33-42. PubMed ID: 29066508
    [No Abstract]   [Full Text] [Related]  

  • 40. Next-Generation Sequencing of Pulmonary Large Cell Neuroendocrine Carcinoma Reveals Small Cell Carcinoma-like and Non-Small Cell Carcinoma-like Subsets.
    Rekhtman N; Pietanza MC; Hellmann MD; Naidoo J; Arora A; Won H; Halpenny DF; Wang H; Tian SK; Litvak AM; Paik PK; Drilon AE; Socci N; Poirier JT; Shen R; Berger MF; Moreira AL; Travis WD; Rudin CM; Ladanyi M
    Clin Cancer Res; 2016 Jul; 22(14):3618-29. PubMed ID: 26960398
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 16.